[1]秦永林,邓 钢,郭金和,等.支架植入对股腘动脉闭塞性病变内膜下成形术后通畅率的影响[J].介入放射学杂志,2012,(04):278-283.
,,et al.The impact of stent implantation on the patency rate of femoropopliteal artery after subintimal angioplasty for occlusive arteriosclerosis [J].journal interventional radiology,2012,(04):278-283.
点击复制
支架植入对股腘动脉闭塞性病变内膜下成形术后通畅率的影响 ()
《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]
- 卷:
-
- 期数:
-
2012年04期
- 页码:
-
278-283
- 栏目:
-
血管介入
- 出版日期:
-
2012-04-28
文章信息/Info
- Title:
-
The impact of stent implantation on the patency rate of femoropopliteal artery after subintimal angioplasty for occlusive arteriosclerosis
- 作者:
-
秦永林; 邓 钢; 郭金和; 滕皋军
-
- Author(s):
-
QIN Yonglin; DENG Gang; Guo Jinhe; TENG Gaojun
-
Department of Interventional Therapy and Vascular Surgery, Zhongda Hospital, Southeast University, Nanjing 210009, China
-
- 文献标志码:
-
A
- 摘要:
-
【摘要】 目的 采用内膜下成形和(或)支架植入治疗股腘动脉闭塞性病变的临床疗效及支架植入对术后通畅率的影响。方法 2007年1月至2009年5月收治下肢股腘动脉闭塞患者43例(43条肢体),其中24例(非支架组)行单纯内膜下成形术,其余19例患者(支架组)在内膜下成形后一期行支架植术。术后行CTA或多普勒超声检查,对部分再狭窄或闭塞病变行再次介入治疗。术后随访1 ~ 27个月。结果 术后12个月保肢率为98%(42/43),围手术期并发症发生率为7%(3/43),2年死亡率为7%(3/43)。随访期内22例出现再狭窄或闭塞,其中非支架组3例闭塞发生在术后1个月内;共有12条肢体行再次介入治疗。非支架组6、12和24个月的一期通畅率分别为83.3% ± 7.6%、74.0% ± 9.2%和56.1% ± 13.5%;支架组分别为89.5% ± 7.0%、77.5% ± 9.9%和32.2% ± 16.6%。非支架组12、24个月的一期辅助通畅率分别为90.9% ± 6.1%和64.2% ± 14.7%;支架组分别为94.4% ± 5.4%和39.0% ± 15.9%);支架组和非支架组整体间差异均无统计学意义P > 0.05。远端血管通畅数目、股腘动脉闭塞类型和吸烟史对内膜下成形术后2年内一期通畅率有显著影响(r = -4.417,2.502,3.115; S χ =1.627,0.955,1.523;P = 0.007,0.009,0.041)。结论 内膜下成形术后不必常规行支架植入;支架植入不会改善术后2年期内的通畅率; 2年期内通畅率与周围血管条件密切相关,吸烟也对预后有重要影响。
参考文献/References:
[1] Bolia A, Brennan J, Bell PR. Recanalisation of femoropopliteal occlusions: improving success rate by subintimal recanalisation[J]. Clin Radiol, 1989, 40: 325.
[2] 肖 亮, 申 景, 黄德生, 等. 糖尿病下肢动脉阻塞性病变介入治疗疗效分析[J]. 介入放射学杂志, 2011, 20: 218 223.
[3] Schwarzwalder U, Zeller T. Belowtheknee revascularization. Advanced techniques[J]. J Cardiovasc Surg (Torino), 2009, 50: 627 634.
[4] Rand T, Lammer J, Rabbia C, et al. Percutaneous transluminal angioplasty versus turbostatic carboncoated stents in infrapopliteal arteries: InPeria II trial[J]. Radiology, 2011, 261: 634 642.
[5] Ko YG, Shin S, Kim KJ, et al. Efficacy of stentsupported subintimal angioplasty in the treatment of long iliac artery occlusions[J]. J Vasc Surg, 2011, 54: 116 122.
[6] Duda SH, Bosiers M, Lammer J, et al. Sirolimuseluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial[J]. J Vasc Interv Radiol, 2005, 16: 331 338.
[7] Duda SH, Bosiers M, Lammer J, et al. Drugeluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: longterm results from the SIROCCO trial[J]. J Endovasc Ther, 2006, 13: 701 710.
[8] Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery[J]. N Engl J Med, 2006, 354: 1879 1888.
[9] Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting[J]. Circulation, 2007, 115: 2745 2749.
[10] 楼文胜, 顾建平, 何 旭, 等. 内膜下成形术治疗股浅动脉长段闭塞[J]. 介入放射学杂志, 2011, 20: 773 777.
[11] Lazaris AM, Tsiamis AC, Fishwick G, et al. Clinical outcome of primary infrainguinal subintimal angioplasty in diabetic patients with critical lower limb ischemia[J]. J Endovasc Ther, 2004, 11: 447 453.
[12] Antusevas A, Aleksynas N, Kaupas RS, et al. Comparison of results of subintimal angioplasty and percutaneous transluminal angioplasty in superficial femoral artery occlusions[J]. Eur J Vasc Endovasc Surg, 2008, 36: 101 106.
[13] Laxdal E, Jenssen GL, Pedersen G, et al. Subintimal angioplasty as a treatment of femoropopliteal artery occlusions[J]. Eur J Vasc Endovasc Surg, 2003, 25: 578 582.
[14] Clair DG, Dayal R, Faries PL, et al. Tibial angioplasty as an alternative strategy in patients with limbthreatening ischemia[J]. Ann Vasc Surg, 2005, 19: 63 68.
[15] Tefera G, Hoch J, Turnipseed WD. Limbsalvage angioplasty in vascular surgery practice[J]. J Vasc Surg, 2005, 41: 988 993.
[16] Hynes N, Akhtar Y, Manning B, et al. Subintimal angioplasty as a primary modality in the management of critical limb ischemia: comparison to bypass grafting for aortoiliac and femoropopliteal occlusive disease[J]. J Endovasc Ther, 2004, 11: 460 471.
[17] Yilmaz S, Sindel T, Ceken K, et al. Subintimal recanalization of long superficial femoral artery occlusions through the retrograde popliteal approach[J]. Cardiovasc Intervent Radiol, 2001, 24: 154 160.
[18] Myers SI, Myers DJ, Ahmend A, et al. Preliminary results of subintimal angioplasty for limb salvage in lower extremities with severe chronic ischemia and limbthreatening ischemia[J]. J Vasc Surg, 2006, 44: 1239 1246.
[19 Giovanetti F, Gargiulo M, Laghi L, et al. Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty[J]. J Endovasc Ther, 2009, 16: 389 396.
[20] Jamsén T, Manninen H, Tulla H, et al. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia[J]. J Vasc Interv Radiol, 2002, 13: 455 463.
[21] Vraux H, Hammer F, Verhelst R, et al. Subintimal angioplasty of tibial vessel occlusions in the treatment of critical limb ischaemia: midterm results[J]. Eur J Vasc Endovasc Surg, 2000, 20: 441 446.
[22] Ingle H, Nasim A, Bolia A, et al. Subintimal angioplasty of isolated infragenicular vessels in lower limb ischemia: longterm results[J]. J Endovasc Ther, 2002, 9: 411 416.
[23] Lazaris AM, Salas C, Tsiamis AC, et al. Factors affecting patency of subintimal infrainguinal angioplasty in patients with critical lower limb ischemia[J]. Eur J Vasc Endovasc Surg, 2006, 32: 668 674.
[24] Hirsch AT, TreatJacobson D, Lando HA, et al. The role of tobacco cessation, antiplatelet and lipidlowering therapies in the treatment of peripheral arterial disease[J]. Vasc Med, 1997, 2: 243 251.
[25] Iida O, Soga Y, Hirano K, et al. Longterm outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis[J]. J Endovasc Ther, 2011, 18: 753 761.
备注/Memo
- 备注/Memo:
-
(收稿日期:2011-11-03)
更新日期/Last Update: